-
Something wrong with this record ?
Semaphorin 4B is an ADAM17-cleaved adipokine that inhibits adipocyte differentiation and thermogenesis
A. Amin, M. Badenes, J. Tüshaus, É. de Carvalho, E. Burbridge, P. Faísca, K. Trávníčková, A. Barros, S. Carobbio, PM. Domingos, A. Vidal-Puig, LF. Moita, S. Maguire, K. Stříšovský, FJ. Ortega, JM. Fernández-Real, SF. Lichtenthaler, C. Adrain
Language English Country Germany
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
PubMed Central
from 2012
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
- MeSH
- Adipokines * metabolism MeSH
- Receptors, Adrenergic, beta metabolism MeSH
- Cell Differentiation MeSH
- Adipocytes, Brown metabolism MeSH
- Lipids MeSH
- Mice MeSH
- Proteomics MeSH
- Semaphorins * genetics metabolism MeSH
- Thermogenesis physiology MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVE: The metalloprotease ADAM17 (also called TACE) plays fundamental roles in homeostasis by shedding key signaling molecules from the cell surface. Although its importance for the immune system and epithelial tissues is well-documented, little is known about the role of ADAM17 in metabolic homeostasis. The purpose of this study was to determine the impact of ADAM17 expression, specifically in adipose tissues, on metabolic homeostasis. METHODS: We used histopathology, molecular, proteomic, transcriptomic, in vivo integrative physiological and ex vivo biochemical approaches to determine the impact of adipose tissue-specific deletion of ADAM17 upon adipocyte and whole organism metabolic physiology. RESULTS: ADAM17adipoq-creΔ/Δ mice exhibited a hypermetabolic phenotype characterized by elevated energy consumption and increased levels of adipocyte thermogenic gene expression. On a high fat diet, these mice were more thermogenic, while exhibiting elevated expression levels of genes associated with lipid oxidation and lipolysis. This hypermetabolic phenotype protected mutant mice from obesogenic challenge, limiting weight gain, hepatosteatosis and insulin resistance. Activation of beta-adrenoceptors by the neurotransmitter norepinephrine, a key regulator of adipocyte physiology, triggered the shedding of ADAM17 substrates, and regulated ADAM17 expression at the mRNA and protein levels, hence identifying a functional connection between thermogenic licensing and the regulation of ADAM17. Proteomic studies identified Semaphorin 4B (SEMA4B), as a novel ADAM17-shed adipokine, whose expression is regulated by physiological thermogenic cues, that acts to inhibit adipocyte differentiation and dampen thermogenic responses in adipocytes. Transcriptomic data showed that cleaved SEMA4B acts in an autocrine manner in brown adipocytes to repress the expression of genes involved in adipogenesis, thermogenesis, and lipid uptake, storage and catabolism. CONCLUSIONS: Our findings identify a novel ADAM17-dependent axis, regulated by beta-adrenoceptors and mediated by the ADAM17-cleaved form of SEMA4B, that modulates energy balance in adipocytes by inhibiting adipocyte differentiation, thermogenesis and lipid catabolism.
Centro de Investigacíon Principe Felipe Valencia Spain
CIBER Fisiopatología de la Obesidad y Nutrición Madrid Spain
Department of Medical Sciences University of Girona Girona Spain
Department of Physiology Faculty of Basic Medical Sciences University of Ilorin Nigeria
Faculty of Veterinary Medicine Lusofona University Lisbon Portugal
Faculty of Veterinary Nursing Polytechnic Institute of Lusofonia Lisbon Portugal
German Center for Neurodegenerative Diseases Munich Germany
Girona Biomedical Research Institute Girona Spain
Instituto de Tecnologia Química da Universidade Nova de Lisboa Oeiras Portugal
Instituto Gulbenkian de Ciência Oeiras Portugal
Munich Cluster for Systems Neurology Munich Germany
Patrick G Johnston Centre for Cancer Research Queen's University Belfast N Ireland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010909
- 003
- CZ-PrNML
- 005
- 20230801132705.0
- 007
- ta
- 008
- 230718s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.molmet.2023.101731 $2 doi
- 035 __
- $a (PubMed)37121509
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Amin, Abdulbasit $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal; Department of Physiology, Faculty of Basic Medical Sciences, University of Ilorin, Nigeria
- 245 10
- $a Semaphorin 4B is an ADAM17-cleaved adipokine that inhibits adipocyte differentiation and thermogenesis / $c A. Amin, M. Badenes, J. Tüshaus, É. de Carvalho, E. Burbridge, P. Faísca, K. Trávníčková, A. Barros, S. Carobbio, PM. Domingos, A. Vidal-Puig, LF. Moita, S. Maguire, K. Stříšovský, FJ. Ortega, JM. Fernández-Real, SF. Lichtenthaler, C. Adrain
- 520 9_
- $a OBJECTIVE: The metalloprotease ADAM17 (also called TACE) plays fundamental roles in homeostasis by shedding key signaling molecules from the cell surface. Although its importance for the immune system and epithelial tissues is well-documented, little is known about the role of ADAM17 in metabolic homeostasis. The purpose of this study was to determine the impact of ADAM17 expression, specifically in adipose tissues, on metabolic homeostasis. METHODS: We used histopathology, molecular, proteomic, transcriptomic, in vivo integrative physiological and ex vivo biochemical approaches to determine the impact of adipose tissue-specific deletion of ADAM17 upon adipocyte and whole organism metabolic physiology. RESULTS: ADAM17adipoq-creΔ/Δ mice exhibited a hypermetabolic phenotype characterized by elevated energy consumption and increased levels of adipocyte thermogenic gene expression. On a high fat diet, these mice were more thermogenic, while exhibiting elevated expression levels of genes associated with lipid oxidation and lipolysis. This hypermetabolic phenotype protected mutant mice from obesogenic challenge, limiting weight gain, hepatosteatosis and insulin resistance. Activation of beta-adrenoceptors by the neurotransmitter norepinephrine, a key regulator of adipocyte physiology, triggered the shedding of ADAM17 substrates, and regulated ADAM17 expression at the mRNA and protein levels, hence identifying a functional connection between thermogenic licensing and the regulation of ADAM17. Proteomic studies identified Semaphorin 4B (SEMA4B), as a novel ADAM17-shed adipokine, whose expression is regulated by physiological thermogenic cues, that acts to inhibit adipocyte differentiation and dampen thermogenic responses in adipocytes. Transcriptomic data showed that cleaved SEMA4B acts in an autocrine manner in brown adipocytes to repress the expression of genes involved in adipogenesis, thermogenesis, and lipid uptake, storage and catabolism. CONCLUSIONS: Our findings identify a novel ADAM17-dependent axis, regulated by beta-adrenoceptors and mediated by the ADAM17-cleaved form of SEMA4B, that modulates energy balance in adipocytes by inhibiting adipocyte differentiation, thermogenesis and lipid catabolism.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a hnědé tukové buňky $x metabolismus $7 D052437
- 650 12
- $a adipokiny $x metabolismus $7 D054392
- 650 _2
- $a buněčná diferenciace $7 D002454
- 650 _2
- $a lipidy $7 D008055
- 650 _2
- $a proteomika $7 D040901
- 650 _2
- $a beta-adrenergní receptory $x metabolismus $7 D011943
- 650 12
- $a semaforiny $x genetika $x metabolismus $7 D039961
- 650 _2
- $a termogeneze $x fyziologie $7 D022722
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Badenes, Marina $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal; Faculty of Veterinary Medicine, Lusofona University, Lisbon, Portugal; Faculty of Veterinary Nursing, Polytechnic Institute of Lusofonia, Lisbon, Portugal
- 700 1_
- $a Tüshaus, Johanna $u German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
- 700 1_
- $a de Carvalho, Érika $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal; Instituto de Tecnologia Química da Universidade Nova de Lisboa (ITQB-Nova), Oeiras, Portugal
- 700 1_
- $a Burbridge, Emma $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal; Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast, N. Ireland
- 700 1_
- $a Faísca, Pedro $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal
- 700 1_
- $a Trávníčková, Květa $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Barros, André $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal
- 700 1_
- $a Carobbio, Stefania $u Centro de Investigacíon Principe Felipe (CIPF), Valencia, Spain; Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK
- 700 1_
- $a Domingos, Pedro M $u Instituto de Tecnologia Química da Universidade Nova de Lisboa (ITQB-Nova), Oeiras, Portugal
- 700 1_
- $a Vidal-Puig, Antonio $u Centro de Investigacíon Principe Felipe (CIPF), Valencia, Spain; Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK
- 700 1_
- $a Moita, Luís F $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal
- 700 1_
- $a Maguire, Sarah $u Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast, N. Ireland
- 700 1_
- $a Stříšovský, Kvido $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Ortega, Francisco J $u Girona Biomedical Research Institute (IDIBGI), Girona, Spain; Department of Medical Sciences, University of Girona, Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), and Institute of Salud Carlos III (ISCIII), Madrid, Spain
- 700 1_
- $a Fernández-Real, José Manuel $u Girona Biomedical Research Institute (IDIBGI), Girona, Spain; Department of Medical Sciences, University of Girona, Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), and Institute of Salud Carlos III (ISCIII), Madrid, Spain
- 700 1_
- $a Lichtenthaler, Stefan F $u German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- 700 1_
- $a Adrain, Colin $u Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal; Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast, N. Ireland. Electronic address: c.adrain@qub.ac.uk
- 773 0_
- $w MED00190571 $t Molecular metabolism $x 2212-8778 $g Roč. 73, č. - (2023), s. 101731
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37121509 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132702 $b ABA008
- 999 __
- $a ok $b bmc $g 1963369 $s 1197174
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 73 $c - $d 101731 $e 20230428 $i 2212-8778 $m Molecular metabolism $n Mol Metab $x MED00190571
- LZP __
- $a Pubmed-20230718